Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-label Study to Evaluate the Safety and Efficacy of CD160-enhanced Autologous BTC-Ag-T Cells in Advanced Biliary Tract Malignancies

NCT07614061 is registered in ClinicalTrials.gov with Shanghai Zhongshan Hospital as lead sponsor.

NCT NCT07614061
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07614061 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-label Study to Evaluate the Safety and Efficacy of CD160-enhanced Autologous BTC-Ag-T Cells in Advanced Biliary Tract Malignancies
Lead sponsor
Shanghai Zhongshan Hospital
Phase
Phase 1
Overall status
Recruiting
Start date
May 31, 2026
Completion date
December 31, 2029
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

biliary tract neoplasms, cholangiocarcinoma, extrahepatic, cholangiocarcinoma, intrahepatic, cholangiocarcinoma, perihilar, gallbladder cancer